There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Rosenberg and colleagues review evidence suggesting that T cells that target tumor
neoantigens arising from cancer mutations are the main mediators of many effective
cancer immunotherapies in humans.